Advances in Antihistamine Therapy: Pharmacology, Mechanisms, Clinical Applications and Future Prospects

Mr. Adinath Gajanan Bhone[1], Mr. Parshwanath Subhashrao Dhoke[2], Miss. Shreya vilas Bhute[3], Mr. V S Suryavanshi[4]
[1,2,3,4]*Prerna Institute of Pharmacy, Parbhani*

Abstract- Antihistamines represent one of the most important therapeutic classes in the management of allergic and inflammatory conditions. These drugs exert their activity primarily through inverse agonism at histamine receptors, predominantly H1, but additional anti-inflammatory, immunomodulatory and receptor-biased actions have expanded their scope. First-generation antihistamines are effective but associated with sedation and anticholinergic effects, whereas newer second- and third-generation agents provide enhanced selectivity, longer duration of action and improved safety profiles. Emerging research highlights their roles in cytokine modulation, mast cell stabilization and treatment of chronic urticaria unresponsive to standard therapy. This review provides an extensive overview of the chemistry, classification, mechanisms, pharmacokinetics, therapeutic applications, adverse reactions, comparative evaluation and future perspectives of antihistamine therapy.

Keywords: Antihistamines, Histamine receptors, Allergy, H1 blockers, Pharmacology, Review article.

I. INTRODUCTION

Histamine is an endogenous biogenic amine synthesized from histidine by histidine decarboxylase. It plays a critical role in immune response, gastric acid secretion, neurotransmission, and allergic reactions. Among four identified histamine receptors (H1, H2, H3, H4), the H1 receptor is primarily responsible for allergic symptoms such as itching, vasodilation, increased vascular permeability, and smooth muscle contraction. Antihistamines—also known as H1 receptor antagonists or inverse agonists—remain the cornerstone of therapy for allergic rhinitis, urticaria, and several hypersensitivity disorders. Since their discovery in the 1930s, their structural and functional evolution has led to improved potency, reduced sedation, longer duration of action, and better safety profiles. Histamine is involved in multiple physiological and pathological processes, including allergic inflammation, immune modulation, gastric acid secretion and neurotransmission. It acts through four receptor subtypes: H1, H2, H3 and H4, each associated with distinct tissue responses. Antihistamines, discovered in the early 20th century, remain vital in treating allergic rhinitis, urticaria, conjunctivitis, anaphylactic reactions and various dermatological disorders. With improved receptor selectivity and reduced side effects, antihistamines are now among the most frequently prescribed medications globally. This review summarizes their evolution, molecular mechanisms, pharmacological profiles, clinical applications, emerging trends and future directions.

II. HISTAMINE: SYNTHESIS, PHYSIOLOGY, AND PATHOPHYSIOLOGICAL ROLE

Histamine is an endogenous biogenic amine that plays a central role in immunological, neurological, and gastrointestinal functions. It is synthesized from the amino acid histidine through a decarboxylation reaction catalyzed by the enzyme histidine decarboxylase (HDC). This enzyme is highly expressed in mast cells, basophils, enterochromaffin-like (ECL) cells of the stomach, and specific neurons within the central nervous system. Once synthesized, histamine is stored in cytoplasmic granules complexed with acidic proteins and heparin, allowing rapid release upon stimulation.

1. Histamine Synthesis and Storage

Histamine formation occurs primarily in mast cells and basophils, which serve as the body's major reservoir. These cells undergo a process of granule maturation where histamine becomes tightly packed along with other inflammatory mediators such as tryptase, heparin, and various cytokines. Outside the

immune system, histamine-producing neurons within the hypothalamus release histamine as a neurotransmitter regulating arousal, circadian rhythm, and appetite. In the gastrointestinal system, ECL cells synthesize histamine to regulate gastric acid secretion through H2 receptor activation on parietal cells.

2. Mechanisms of Histamine Release

Histamine can be released through immune-mediated and non–immune-mediated pathways:

IgE-mediated degranulation: Seen in allergic responses when cross-linking of IgE antibodies on mast cells triggers immediate mediator release.

Complement-mediated: Activation of C3a and C5a can directly stimulate histamine exocytosis.

Non-immune triggers: Physical stimuli (cold, heat, vibration), drugs (opioids, radiocontrast media), toxins, and neuropeptides can cause direct mast cell activation. Once released, histamine's action is rapid but short-lasting, as it is quickly metabolized by histamine N-methyltransferase (HNMT) and diamine oxidase (DAO).



3. Histamine Receptors and Physiological Roles

Histamine exerts its actions through four distinct G-protein–coupled receptors: Receptor Distribution and Major Physiological Functions

H1 Endothelium, smooth muscle, sensory nerves, CNS Vasodilation, increased vascular permeability, bronchoconstriction, pruritus, wakefulness

H2 Gastric parietal cells, heart, vascular smooth muscle Gastric acid secretion, cardiac stimulation

H3 Presynaptic neurons in CNS and PNS Modulates release of acetylcholine, dopamine, norepinephrine, and serotonin

H4 Bone marrow, eosinophils, mast cells, basophils Chemotaxis, immune cell activation, allergic inflammation The H1 receptor is primarily responsible for allergic symptoms such as erythema, urticaria, nasal congestion, itching, and bronchospasm—making it the principal target for therapeutic antihistamines.



4. Pathophysiological Role of Histamine

Histamine contributes to several physiological processes, but excessive or dysregulated release leads to pathological conditions:

4.1 Allergic Inflammation

During allergic rhinitis, urticaria, atopic dermatitis, or anaphylaxis, histamine triggers: Rapid vasodilation, Increased vascular permeability → edema, wheal formation, Sensory nerve activation → itching, Bronchial smooth muscle contraction. These actions collectively produce the classical hallmark symptoms of immediate hypersensitivity reactions.

4.2 Immune Regulation

Histamine acts as an immunomodulator: Promotes Th2 cell differentiation, Enhances dendritic cell antigen presentation, Regulates eosinophil migration

through H4 receptors. This positions histamine as a key mediator linking innate and adaptive immunity.

4.3 Gastric Physiology

Histamine released by ECL cells binds to H2 receptors on parietal cells, stimulating: Gastric acid secretion, Pepsin release, Maintenance of mucosal tone Overproduction can contribute to peptic ulcer disease and Zollinger–Ellison syndrome.

4.4 Neurotransmission

Histaminergic neurons influence: Wakefulness and sleep-wake cycling, Feeding behavior, Cognitive functions, Thermoregulation Dysfunction in histamine neurotransmission has been associated with

sleep disorders and certain neuropsychiatric conditions.

III. CLASSIFICATION OF ANTIHISTAMINES

First-Generation (Sedating) H1 Antihistamines

First-generation antihistamines were introduced in the 1930s–1950s. Their physicochemical properties—high lipophilicity, low molecular weight, and weak plasma protein binding—enable them to readily cross the blood–brain barrier (BBB). As a result, they produce prominent sedation, psychomotor impairment, and anticholinergic effects.

Chemical Classes

Ethanolamines: Diphenhydramine, Doxylamine

Ethylenediamines: Tripelennamine

Propylamines (alkylamines): Chlorpheniramine, Brompheniramine

Phenothiazines: Promethazine

Piperazines: Hydroxyzine, Cyclizine

Second-Generation (Non-Sedating) H1 Antihistamines

Second-generation agents were developed to reduce CNS adverse effects. These drugs are relatively lipophobic, possess high protein binding, and are substrates for P-glycoprotein efflux pumps, which minimize brain entry. They demonstrate longer half-lives, allowing once-daily dosing.

Examples:

Loratadine, Cetirizine, Fexofenadine, Azelastine, Rupatadine,

Desloratidine, Mizolastine, Levocetrazine

IV. MECHANISM OF ACTION

Antihistamines act primarily on H1 histamine receptors, but unlike traditional antagonists that simply block receptor activity, most modern antihistamines function as inverse agonists. This means they preferentially bind to the inactive conformation of the H1 receptor and stabilize it, thereby reducing its basal (constitutive) activity even in the absence of histamine. The H1 receptor is a G-protein coupled receptor (GPCR) linked predominantly to the Gq/11 signaling pathway. When histamine binds to the receptor, it activates phospholipase-C, leading to the generation of IP3 and DAG, increased intracellular calcium, and subsequent smooth muscle contraction, vasodilation, vascular permeability, and sensory nerve stimulation. Antihistamines inhibit this cascade by preventing receptor activation and downstream signal transduction.

In addition to inhibiting receptor-mediated second messenger pathways, many second- and third-generation antihistamines exhibit anti-inflammatory effects independent of H1 receptor blockade. These include attenuation of cytokine release (such as IL-4, IL-6, and TNF-α), suppression of eosinophil recruitment, inhibition of adhesion molecule expression on endothelial cells, and reduction of mast-cell mediator release. These immunomodulatory effects play a key role in improving chronic allergic conditions such as chronic spontaneous urticaria and persistent allergic rhinitis.

Furthermore, antihistamines vary in their ability to penetrate the central nervous system. First-generation antihistamines are lipophilic and cross the blood–brain barrier easily, leading to central H1 receptor blockade and sedation. In contrast, newer antihistamines are more polar and are substrates for P-glycoprotein efflux pumps, limiting CNS penetration and reducing sedative potential. Their receptor selectivity, prolonged receptor occupancy, and slow dissociation kinetics contribute to their longer duration of action

and better tolerability. Thus, the mechanism of antihistamines encompasses not only receptor blockade but also modulation of inflammatory pathways and pharmacokinetic properties that influence clinical efficacy and safety.

Pharmacokinetics

Absorption: Most agents are rapidly absorbed orally, with onset within 15–60 minutes.

Distribution: First-generation agents widely distribute into CNS; second- generation remain peripheral.

Metabolism: Loratadine → metabolized by CYP3A4
Cetirizine → minimal hepatic metabolism
Fexofenadine → non-hepatic elimination

Excretion: Renal and fecal routes depending on structure.

V. THERAPEUTIC USES OF ANTIHISTAMINES

Antihistamines constitute one of the most widely utilized pharmacological classes for managing allergic and hypersensitivity-related disorders. Their therapeutic utility arises from their ability to selectively block or inversely modulate H1 receptors, thereby counteracting the biological actions of endogenous histamine released during immune activation. Although originally introduced for symptomatic relief in allergic conditions, ongoing research has significantly expanded their clinical applications. Their uses now span respiratory, dermatological, ocular, gastrointestinal, and even neurological indications.

1.Allergic Rhinitis

Antihistamines are considered first-line treatment for both seasonal and perennial allergic rhinitis. By reducing histamine-mediated nasal itching, rhinorrhea, sneezing, and conjunctival irritation, second- and third-generation agents (e.g., fexofenadine, loratadine, bilastine, desloratadine) offer rapid symptom control with minimal sedation. Intranasal antihistamines like azelastine provide additional benefit for patients with moderate to severe symptoms.

2.Urticaria (Acute and Chronic)

Modern guidelines recommend non-sedating antihistamines as the initial therapy for urticaria. They alleviate wheal formation and pruritus through suppression of H1-mediated vascular permeability. In chronic spontaneous urticaria, doses may be increased up to four-fold for better symptom control. Drugs like levocetirizine, cetirizine, and desloratadine are preferred for long-term management due to their safety profile.

3.Anaphylaxis (Adjunctive Therapy)

Although epinephrine remains the lifesaving intervention in anaphylaxis, antihistamines are essential adjuncts for alleviating cutaneous manifestations such as hives, flushing, and itching. They do not prevent airway obstruction or shock but improve patient comfort once stabilization is achieved.

4.Allergic Conjunctivitis

Topical antihistamine eye drops, alone or in combination with mast-cell stabilizers, reduce ocular itching, redness, and tearing. Agents like ketotifen, olopatadine, and azelastine ophthalmic preparations provide rapid relief and are preferred over systemic therapy for isolated ocular symptoms.

5.Dermatological Disorders

Antihistamines are widely used in dermatological conditions associated with pruritus. Atopic dermatitis: Second-generation antihistamines are used primarily for night time itching, although they do not modify inflammation directly. Contact dermatitis/ insect bites: Provide symptomatic relief from itching and swelling. Dermographism and physical urticarias: Regular antihistamine therapy reduces exaggerated wheal responses.

6.Motion Sickness and Vestibular Disorders

First-generation antihistamines such as promethazine, dimenhydrinate, and cyclizine possess antiemetic and anticholinergic properties, making them effective in motion sickness and vestibular dysfunction. They reduce nausea and vertigo by acting on central vestibular pathways.

7.Insomnia (Short-term Use)

Due to their sedative effect, older antihistamines like diphenhydramine and doxylamine are commonly used

as over-the-counter sleep aids. However, their long-term use is discouraged because of tolerance and anticholinergic adverse effects.

8.Anxiety and Pre-operative Sedation

Hydroxyzine, a first-generation antihistamine, has anxiolytic properties due to its central H1 and partial serotonergic antagonism. It is approved for short-term treatment of anxiety and is also used for pre-operative sedation

9.Food Allergies and Drug Reactions

Antihistamines provide symptomatic relief in mild-to-moderate allergic reactions triggered by foods, insect stings, or drugs. They help reduce itching, erythema, and urticaria, though they cannot prevent severe systemic reactions.

10.Gastrointestinal and Respiratory Indications

Although less common, antihistamines may be used in: Mastocytosis-related symptoms such as flushing and pruritus Allergic asthma as adjunct therapy to reduce rhinitis-associated triggers Irritable larynx syndrome due to histamine-mediated throat irritation Dual-acting agents (e.g., rupatadine) showing benefit in inflammatory diseases where PAF plays a role.



VI. CONCLUSION

Antihistamines remain cornerstone agents in the management of allergic and inflammatory disorders. Their evolution from sedating first-generation drugs to modern selective molecules has significantly improved patient safety and efficacy. Continued exploration of receptor biology and inflammatory mechanisms promises development of even more targeted and effective therapies.

REFERENCE

[1] Church, M. K., & Maurer, M. (2021). H1-antihistamines and their evolving role in allergy management. Allergy, 76(6), 1625–1637.
[2] Simons, F. E. R., & Simons, K. J. (2011). Histamine and H1- antihistamines: Celebrating a century of progress. Journal of Allergy and Clinical Immunology, 128(6), 1139–1150.
[3] Saini, S. S. (2014). Chronic spontaneous urticaria: New insights and current management strategies. Journal of Allergy and Clinical Immunology, 133(5), 1270–1280.
[4] Gillman, S. A., & Kaplan, A. P. (2019). Advances in antihistamine therapy. Expert Opinion on Pharmacotherapy, 20(10), 1235–1247.
[5] Maiti, R., & Rahman, S. (2019). Second-generation antihistamines: Present trends and future prospects. International Journal of Basic & Clinical Pharmacology, 8(2), 230–236.
[6] Zuberbier, T., Aberer, W., Asero, R., et al. (2022). The EAACI guidelines for urticaria management. Allergy, 77(3), 734–766.
[7] Scadding, G. K. (2015). Optimal management of allergic rhinitis. Therapeutic Advances in Chronic Disease, 6(5), 167–177.
[8] Bernstein, J. A. (2017). H1-antihistamines in allergic disease: Mechanisms and clinical utility. Clinical Reviews in Allergy & Immunology, 53(2), 183–194.
[9] Passalacqua, G., & Canonica, G. W. (2016). New-generation antihistamines: An update. Clinical and Molecular Allergy, 14(1), 1–10.
[10] Kuna, P., Jurkiewicz, D., & Mackiewicz, B. (2019). Modern intranasal antihistamines in allergic diseases. Journal of Asthma & Allergy, 12, 263–272
[11] Devillier, P., Humbert, M., & Salvator, H. (2020). Bilastine: A modern non-sedating antihistamine. Drugs, 80(2), 151–164.
[12] Sánchez-Borges, M. (2010). Levocetirizine in the treatment of allergic disorders. Expert Opinion on Pharmacotherapy, 11(2), 275–283.
[13] Church, D. S., & Church, M. K. (2013). Pharmacology of antihistamines. World Allergy Organization Journal, 6(1), 1–10.
[14] O'Connor, A., & O'Mahony, L. (2018). Histamine, receptors, and antihistamines: Clinical

relevance. Clinical & Experimental Allergy, 48(2), 164–173.

[15] Coward, W. R., & Holgate, S. T. (2015). H4 receptor antagonists in allergic inflammation. Allergy & Asthma Immunology Research, 7(4), 300–308.

[16] Zampeli, E., & Tiligada, E. (2009). The role of histamine H4 receptor in immune regulation. British Journal of Pharmacology, 157(1), 24–33.

[17] Beale, J., et al. (2015). Antihistamines in clinical practice: A comparative evaluation. Therapeutics and Clinical Risk Management, 11, 145–157.

[18] Bousquet, J., et al. (2020). Next-generation antihistamines in allergic rhinitis. Clinical & Translational Allergy, 10(1), 1–12.

[19] Maurer, M., et al. (2013). Up-dosing of second-generation antihistamines in chronic urticaria. Allergy, 68(7), 880–886.

[20] FDA. (2023). Antihistamine drug information updates. U.S. Food and Drug Administration. Retrieved from https://www.fda.gov (use in-text citation only)